Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia

Nonfiction, Health & Well Being, Medical, Specialties, Internal Medicine, Hematology, Oncology
Cover of the book Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia by , Springer Japan
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9784431557142
Publisher: Springer Japan Publication: November 5, 2015
Imprint: Springer Language: English
Author:
ISBN: 9784431557142
Publisher: Springer Japan
Publication: November 5, 2015
Imprint: Springer
Language: English

Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia provides a comprehensive understanding of the recent molecular genetics of Chronic Myelogenous Leukemia (CML) and a characterization of the molecular targets for drug development. Included are therapeutic implications, diagnosis, and prognosis for understanding and facilitating daily practice in the management of patients with CML.

Understanding of the pathogenesis and therapy of hematological malignancies such as CML has grown significantly in recent years. This development owe much to the progress in molecular biology and now makes a major contribution to diagnosis and to treatment that pharmacologically targets the molecular events of CML. Molecular targeting therapy with newly developed agents such as small molecules and antibodies for hematological malignancies are being discovered after years of research. Some of these, including tyrosine kinase inhibitors such as imatinib, nilotinib, and dasatinib, lead to increased survival rates and improved therapies. With the opinion leaders of basic and clinical research in the field as authors, this book reviews recent advances in the biology of CML.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia provides a comprehensive understanding of the recent molecular genetics of Chronic Myelogenous Leukemia (CML) and a characterization of the molecular targets for drug development. Included are therapeutic implications, diagnosis, and prognosis for understanding and facilitating daily practice in the management of patients with CML.

Understanding of the pathogenesis and therapy of hematological malignancies such as CML has grown significantly in recent years. This development owe much to the progress in molecular biology and now makes a major contribution to diagnosis and to treatment that pharmacologically targets the molecular events of CML. Molecular targeting therapy with newly developed agents such as small molecules and antibodies for hematological malignancies are being discovered after years of research. Some of these, including tyrosine kinase inhibitors such as imatinib, nilotinib, and dasatinib, lead to increased survival rates and improved therapies. With the opinion leaders of basic and clinical research in the field as authors, this book reviews recent advances in the biology of CML.

More books from Springer Japan

Cover of the book Clinical Applications of Magnetoencephalography by
Cover of the book Chile’s Salmon Industry by
Cover of the book Symmetry and Economic Invariance by
Cover of the book Computational Simulation in Architectural and Environmental Acoustics by
Cover of the book Vascular Ultrasound by
Cover of the book Functional Evaluation of Stroke Patients by
Cover of the book Firms’ Location Selections and Regional Policy in the Global Economy by
Cover of the book Microsurgical Anatomy and Surgery of the Posterior Cranial Fossa by
Cover of the book Cognitive Neuroscience Robotics B by
Cover of the book Eels and Humans by
Cover of the book Neurogenesis in the Adult Brain II by
Cover of the book Geometry and Topology of Manifolds by
Cover of the book Economics of Pessimism and Optimism by
Cover of the book Renal Cell Carcinoma by
Cover of the book Microcirculation in Fractal Branching Networks by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy